Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Jeffrey V. Matous, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Meera Mohan, Jose C. Cruz, Rajneesh Nath, Faiz Anwer, Adriana Rossi, Myo Htut, Shahbaz A. Malik, Srinivas Ghatta, Myles Dillon, Wendy Ying, Lynn Navale, Erin E. Karski, Arun Balakumaran, Shaji K. Kumar

Blood (2022) 140 (Supplement 1): 4620–4622.

https://doi.org/10.1182/blood-2022-158231

Published: 2022

Journal Articles

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T

Sattva S. Neelapu, Rajneesh Nath, Javier Munoz, Michael Tees, David B. Miklos, Matthew J. Frank, Shahbaz A. Malik, Don Stevens, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Anh Nguyen, Frederick L. Locke

Blood (2021) 138 (Supplement 1): 3878.

https://doi.org/10.1182/blood-2021-146038

Published: 2021

Journal Articles

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Lazaros J. Lekakis, Frederick L. Locke, Michael Tees, Sattva S. Neelapu, Shahbaz A. Malik, Mehdi Hamadani, Matthew J. Frank, Leslie L. Popplewell, Jeremy S. Abramson, Sven de Vos, Javier Munoz, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Xiangdong Zhou, David B. Miklos

Blood (2021) 138 (Supplement 1): 649.

https://doi.org/10.1182/blood-2021-146045

Published: 2021

Journal Articles

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 651.

https://doi.org/10.1182/blood-2021-145572

Published: 2021

Journal Articles

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Sham Mailankody, MBBS, Jeffrey V. Matous, MD, Michaela Liedtke, MD, Surbhi Sidana, MD, Shahbaz Malik, MD, Rajneesh Nath, MD, Olalekan O. Oluwole, MBBS, MPH, Erin E. Karski, Wade Lovelace, Xiangdong Zhou, PhD, Srinand Nandakumar, PhD, Arun Balakumaran, MD PhD, Parameswaran Hari, MD MRCP

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-140641

Published: 2020

Journal Articles

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Eunhee Kim, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz

Blood (2019) 134 (14): 1144–1153.

https://doi.org/10.1182/blood.2019000324

Published: 2019

Includes: Supplemental data

Journal Articles

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, MD, Robert W. Chen, MD, Hun Ju Lee, MD, Philippe Armand, MD PhD, Nathalie A Johnson, MD PhD, Pauline Brice, MD, John Radford, MD FRCP, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian Von Tresckow, MD, Margaret A. Shipp, MD, Eunhee Kim, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2018) 132 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2018-99-117045

Published: 2018

Journal Articles

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Blood (2018) 132 (Supplement 1): 228.

https://doi.org/10.1182/blood-2018-99-110220

Published: 2018

Journal Articles

Patient-Reported Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab Monotherapy, Results of a Phase 2 Study

Bastian von Tresckow, Michelle A. Fanale, MD, Kirit M Ardeshna, MA MDFRCP FRCPath, Robert W. Chen, MD, Julia Meissner, MD, Franck Morschhauser, MD PhD, Craig H. Moskowitz, MD, Pier Luigi Zinzani, MD, Hilde Giezek, Arun Balakumaran, MD PhD, Monika Raut, PhD MS, Thao Vo, Pauline Brice, MD

Blood (2017) 130 (Supplement 1): 2169.

https://doi.org/10.1182/blood.V130.Suppl_1.2169.2169

Published: 2017

Journal Articles

Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial

Pier Luigi Zinzani, MD, Catherine Thieblemont, MD PhD, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, MD PhD, Alejandro Majlis, MD, Laura Fogliatto, MD, Dolores Caballero, MD PhD, Beth Christian, MD, Zafer Gulbas, MD, Muhit Özcan, MD, Gilles Andre Salles, MD PhD, Margaret A. Shipp, MD, Arkendu Chatterjee, Robert J Orlowski, Arun Balakumaran, MD PhD, Philippe Armand, MD PhD

Blood (2017) 130 (Supplement 1): 2833.

https://doi.org/10.1182/blood.V130.Suppl_1.2833.2833

Published: 2017

Journal Articles

Clinical Outcomes of Patients with 3 rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group

Paul Broeckelmann, Horst Mueller, PhD, Esra Kücüksarioglan, Peter Kaskel, MD MBA, Veronika Metterlein, MPH, Hilde Giezek, MSc Biostatistics, Arun Balakumaran, MD PhD, Monika Raut, PhD MS, Andreas Engert, MD, Bastian von Tresckow

Blood (2017) 130 (Supplement 1): 2793.

https://doi.org/10.1182/blood.V130.Suppl_1.2793.2793

Published: 2017

Journal Articles

Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

Craig H. Moskowitz, MD, Robert W. Chen, MD, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD, Theodoros P. Vassilakopoulos, MD PhD, Gregory V. Goldmacher, MD PhD MBA, Jianxin Lin, MS, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Gilles Salles, MD PhD

Blood (2017) 130 (Supplement 1): 4085.

https://doi.org/10.1182/blood.V130.Suppl_1.4085.4085

Published: 2017

Journal Articles

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

Pier Luigi Zinzani, Vincent Ribrag, Craig H. Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Yayan Zhang, Sabine Chlosta, Margaret A. Shipp, Philippe Armand

Blood (2017) 130 (3): 267–270.

https://doi.org/10.1182/blood-2016-12-758383

Published: 2017

Includes: Supplemental data

Journal Articles

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

Craig H. Moskowitz, MD, Pier Luigi Zinzani, MD PhD, Michelle A. Fanale, MD, Philippe Armand, MD PhD, Nathalie A. Johnson, John A. Radford, MD, Vincent Ribrag, MD, Daniel Molin, MD PhD, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian von Tresckow, MD, Margaret A. Shipp, MD, Eric Gustafson, PhD, Yinghua Zhang, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM, Robert W Chen, MD

Blood (2016) 128 (22): 1107.

https://doi.org/10.1182/blood.V128.22.1107.1107

Published: 2016

Journal Articles

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

Philippe Armand, MD PhD, Margaret A. Shipp, MD, Vincent Ribrag, MD, Jean-Marie Michot, MD, Pier Luigi Zinzani, MD PhD, John Kuruvilla, MD, Ying Zhu, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2016) 128 (22): 1108.

https://doi.org/10.1182/blood.V128.22.1108.1108

Published: 2016

Journal Articles

Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment

Guillermo Garcia-Manero, MD, Martin S. Tallman, MD, Giovanni Martinelli, MD, Vincent Ribrag, MD, Hui Yang, MD PhD, Arun Balakumaran, MD PhD SM, Sabine Chlosta, MD, Yayan Zhang, PhD, B. Douglas Smith, MD

Blood (2016) 128 (22): 345.

https://doi.org/10.1182/blood.V128.22.345.345

Published: 2016

Journal Articles

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

Pier Luigi Zinzani, MD PhD, Vincent Ribrag, MD, Craig H. Moskowitz, MD, Jean-Marie Michot, MD, John Kuruvilla, MD, Arun Balakumaran, MD PhD SM, Yayan Zhang, PhD, Patricia Marinello, PharmD, Sabine Chlosta, MD, Eric Gustafson, PhD, Margaret A. Shipp, MD, Philippe Armand, MD PhD

Blood (2016) 128 (22): 619.

https://doi.org/10.1182/blood.V128.22.619.619

Published: 2016

Journal Articles

Utilization Patterns and Resource Use in Relapse/Refractory Hodgkin Lymphoma (rrHL) Patients Treated with Brentuximab Vedotin (BV)

Changxia Shao, PhD, Jinan Liu, PhD, Wei Zhou, PhD, Monika Kumar Raut, PhD, Matthew Monberg, PhD, Xiting Cao, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM

Blood (2016) 128 (22): 2377.

https://doi.org/10.1182/blood.V128.22.2377.2377

Published: 2016

Journal Articles

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

Jesus San Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Jatin J. Shah, MD, Enrique M. Ocio, MD PhD, Paula Rodriguez-Otero, MD PhD, Donna Reece, MD, Nikhil C. Munshi, MD, David Avigan, MD, Yang Ge, PhD, Arun Balakumaran, MD PhD SM, Patricia Marinello, PharmD, Robert Z. Orlowski, MD PhD, David Siegel, MD PhD

Blood (2015) 126 (23): 505.

https://doi.org/10.1182/blood.V126.23.505.505

Published: 2015

Journal Articles

Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Pier Luigi Zinzani, MD PhD, Vincent Ribrag, MD, Craig H. Moskowitz, MD, Jean-Marie Michot, John Kuruvilla, MD, Arun Balakumaran, MD PhD SM, Ellen Snyder, PhD, Patricia Marinello, PharmD, Margaret A. Shipp, MD, Philippe Armand, MD PhD

Blood (2015) 126 (23): 3986.

https://doi.org/10.1182/blood.V126.23.3986.3986

Published: 2015

NARROW

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Patient-Reported Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab Monotherapy, Results of a Phase 2 Study

Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial

Clinical Outcomes of Patients with 3 rd or Higher Relapsed Classical Hodgkin Lymphoma: Results from the German Hodgkin Study Group

Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study

Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

Utilization Patterns and Resource Use in Relapse/Refractory Hodgkin Lymphoma (rrHL) Patients Treated with Brentuximab Vedotin (BV)

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only